These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8158355)

  • 1. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension.
    Tunny TJ; Ziesak MD; Armstrong R; Klemm SA; Stowasser M; Finn WL; Gordon RD
    J Hypertens Suppl; 1993 Dec; 11(5):S222-3. PubMed ID: 8158355
    [No Abstract]   [Full Text] [Related]  

  • 2. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
    Bevan EG; Connell JM; Doyle J; Carmichael HA; Davies DL; Lorimer AR; McInnes GT
    J Hypertens; 1992 Jul; 10(7):607-13. PubMed ID: 1321186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
    O'Connell JE; Jardine AG; Davidson G; Connell JM
    J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
    Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
    Hirata Y; Suzuki Y; Suzuki E; Hayakawa H; Kimura K; Goto A; Omata M; Minamino N; Kangawa K; Matsuo H
    J Hypertens; 1994 Apr; 12(4):367-74. PubMed ID: 8064160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
    Richards AM; Wittert GA; Crozier IG; Espiner EA; Yandle TG; Ikram H; Frampton C
    J Hypertens; 1993 Apr; 11(4):407-16. PubMed ID: 8390508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats.
    Hirata Y; Suzuki E; Hayakawa H; Matsuoka H; Sugimoto T; Kangawa K; Matsuo H
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):283-90. PubMed ID: 7511759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No effect of the oral neutral endopeptidase inhibitor candoxatril, on bronchomotor tone and histamine reactivity in asthma.
    Angus RM; McCallum MJ; Nally JE; Thomson NC
    Eur Respir J; 1994 Jun; 7(6):1084-9. PubMed ID: 7925877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients.
    Johnson AG; Pearce GL; Danoff TM
    J Hum Hypertens; 2006 Jul; 20(7):496-503. PubMed ID: 16543907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.
    Ando S; Rahman MA; Butler GC; Senn BL; Floras JS
    Hypertension; 1995 Dec; 26(6 Pt 2):1160-6. PubMed ID: 7498988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction.
    Yoshida K; Yasujima M; Casley DJ; Johnston CI
    Jpn Circ J; 1998 Sep; 62(9):680-6. PubMed ID: 9766707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension.
    Singer DR; Markandu ND; Buckley MG; Miller MA; Sagnella GA; MacGregor GA
    Hypertension; 1991 Dec; 18(6):798-804. PubMed ID: 1835959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
    Kentsch M; Otter W; Drummer C; Nötges A; Gerzer R; Müller-Esch G
    Eur J Clin Pharmacol; 1996; 51(3-4):269-72. PubMed ID: 9010697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure.
    Kimmelstiel CD; Perrone R; Kilcoyne L; Souhrada J; Udelson J; Smith J; de Bold A; Griffith J; Konstam MA
    Cardiology; 1996; 87(1):46-53. PubMed ID: 8631044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of atrial natriuretic peptide in urine from rats treated with a neutral endopeptidase inhibitor.
    Suzuki E; Hirata Y; Matsuoka H; Sugimoto T; Hayakawa H; Sugimoto T; Kangawa K; Minamino N; Matsuo H
    Biochem Biophys Res Commun; 1992 Feb; 182(3):1270-6. PubMed ID: 1531753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure.
    Westheim AS; Bostrøm P; Christensen CC; Parikka H; Rykke EO; Toivonen L
    J Am Coll Cardiol; 1999 Nov; 34(6):1794-801. PubMed ID: 10577572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.
    Elsner D; Müntze A; Kromer EP; Riegger GA
    Am J Cardiol; 1992 Aug; 70(4):494-8. PubMed ID: 1386491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man.
    O'Connell JE; Jardine AG; Davies DL; McQueen J; Connell JM
    Clin Sci (Lond); 1993 Jul; 85(1):19-26. PubMed ID: 8149689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.
    Northridge DB; Newby DE; Rooney E; Norrie J; Dargie HJ
    Am Heart J; 1999 Dec; 138(6 Pt 1):1149-57. PubMed ID: 10577447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.